What is the recommended treatment for type 1 hepatorenal syndrome?

Treatment for Type 1 HRS (HRS-AKI)

The first-line treatment for type 1 hepatorenal syndrome is a vasoconstrictor (terlipressin or norepinephrine) combined with intravenous albumin, with the goal of reversing renal dysfunction and improving survival. 1

Initial Management Steps

Before starting vasoconstrictor therapy, immediately:

• Stop all diuretics once AKI is diagnosed
• Consider withholding non-selective beta-blockers, especially if the patient is hypotensive
• Assess volume status carefully—fixed-dose albumin in unselected patients can cause harmful volume overload and pulmonary edema 2

First-Line Pharmacologic Treatment

Vasoconstrictor Selection

Terlipressin (where available):

• Start at 1 mg IV every 4-6 hours
• Increase to 2 mg every 4-6 hours if serum creatinine doesn't decrease by ≥25% by day 3
• Continue until creatinine falls below 1.5 mg/dL (typically 14 days) 1, 3
• The CONFIRM trial demonstrated 29.1% vs 15.8% reversal rate compared to placebo (P=0.012) 1
• Critical caveat: Terlipressin carries significant risk of respiratory failure (11% mortality from respiratory disorders vs 2% with placebo) and ischemic complications (12% of patients) 4, 3
• Consider continuous IV infusion (starting 2 mg/day, up to 12 mg/day) to reduce ischemic side effects 1

Norepinephrine (equally effective alternative):

• Start at 0.5 mg/hour as continuous IV infusion (requires ICU setting)
• Titrate every 4 hours in 0.5 mg/hour increments (maximum 3 mg/hour)
• Goal: increase mean arterial pressure by ≥10 mm Hg OR increase urine output >200 mL/4 hours 1, 3
• Preferred in many ICU settings given terlipressin's respiratory risks and lack of FDA approval in North America 2

Albumin Co-Administration

• Day 1: 1 g/kg IV
• Subsequent days: 40-50 g/day continued throughout vasoconstrictor therapy 1, 3
• Important: Tailor albumin to individual volume status—monitor closely for pulmonary edema, as recent data show harm from fixed-dose protocols in unselected patients 2

Treatment Duration and Response Assessment

• Continue vasoconstrictors up to 14 days (occasionally longer if creatinine very elevated at baseline)
• Discontinue if no response after 4 days at maximum tolerated doses 1
• Predictors of response (assess at day 3):
  • Serum bilirubin <10 mg/dL (67% response rate vs 13% if ≥10 mg/dL)
  • Mean arterial pressure increase ≥5 mm Hg (73% response rate vs 36% if <5 mm Hg) 5

Therapies to Avoid

Midodrine plus octreotide: Much lower efficacy than terlipressin or norepinephrine—should be abandoned as primary therapy 1, 2

TIPS: Not recommended for HRS-AKI due to insufficient data and high contraindication rate in this population 1, 3

Renal Replacement Therapy

Initiate RRT based on clinical grounds:

• Worsening kidney function despite vasoconstrictors
• Severe electrolyte disturbances (acidosis, hyperkalemia, hyponatremia) unresponsive to medical management
• Volume overload with diuretic intolerance
• Continuous RRT is preferred over intermittent hemodialysis 1

Definitive Treatment

Liver transplantation remains the only curative therapy—all pharmacologic interventions serve as bridges to transplantation 1, 6

Key Clinical Pitfalls

1. Delayed diagnosis: HRS-AKI is no longer a diagnosis of exclusion and may coexist with acute tubular injury—diagnose within 24 hours to allow prompt treatment 2
2. Fixed albumin dosing: Blindly following albumin protocols without assessing volume status risks fatal pulmonary edema 2
3. Terlipressin in high-risk patients: Exclude severe cardiovascular disease and monitor aggressively for respiratory failure 4
4. Using midodrine/octreotide: This combination lacks efficacy and delays effective treatment 2
5. Continuing diuretics: These worsen renal perfusion and must be stopped immediately 1